Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698936 | Clinical Oncology | 2011 | 10 Pages |
Abstract
This schedule of synchronous capecitabine for locally advanced SCCHN is well tolerated. The local control in this series compares favourably with other synchronous chemoradiotherapy reports. Chronic dysphagia and tube dependence is uncommon with this approach. Capecitabine as targeted therapy given with each fraction of radiotherapy and administered orally may have significant advantages over intravenous, 3 weekly cisplatin.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Jegannathen, K. Mais, A. Sykes, L. Lee, B. Yap, A. Birzgalis, J. Homer, W.D. Ryder, N. Slevin,